Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colossolactone III is a naturally occurring triterpenoid isolated from the Vietnamese mushroom *Ganoderma colossum*. It is structurally characterized by the presence of a six-membered lactone ring (ring D). Research presented at the AACR has evaluated its potential as a chemotherapeutic agent, specifically investigating its antioxidant activity and cytotoxicity against solid tumor cell lines, including breast (MCF-7), cervix (HeLa), colorectal (HCT-116), and liver (HepG2) cancers. While it exhibits weak antioxidant properties (EC50 of approximately 100.81 µM), its cytotoxic potency in early in-vitro studies was found to be lower than other related compounds in the colossolactone family, such as colossolactone IV.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colossolactone III.